欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Revolade
适用类别Human
治疗领域Purpura, Thrombocytopenic, Idiopathic;Anemia, Aplastic
通用名/非专利名称eltrombopag
活性成分Eltrombopag
产品号EMEA/H/C/001110
患者安全信息No
许可状态Authorised
ATC编码B02BX05
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2010/03/11
上市许可开发者/申请人/持有人Novartis Europharm Limited
人用药物治疗学分组Other systemic hemostatics;Antihemorrhagics
兽用药物治疗学分组
审评意见日期2009/12/17
欧盟委员会决定日期2024/11/25
修订号35
治疗适应症Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1). Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1). Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1). Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1).
适用物种
兽用药物ATC编码
首次发布日期2018/07/06
最后更新日期2024/11/28
产品说明书https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/revolade
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase